Council for europe portal
Language : en Search
Choose language
European Pharmacopoeia / Monograph News 21 January 2020 Strasbourg, France
The European Pharmacopoeia (Ph. Eur.) 9th Edition has been obsolete since 1 January 2020. Consequently, the 9th Edition online and all previous versions, including the Ph. Eur. archives for 9th Edition clients, will no longer be accessible starting 1 March 2020. The Ph. Eur. 10th...
European Pharmacopoeia / Monograph News 16 January 2020 Strasbourg, France
The European Pharmacopoeia Commission adopted a new monograph, on Rosuvastatin tablets (3008), at its 163rd session in March 2019. The monograph was published in Supplement 10.1 of the European Pharmacopoeia (Ph. Eur.), available since October 2019, and will become effective on 1...
European Pharmacopoeia / Monograph News 16 January 2020 Strasbourg, France
With a view to improving the correspondence between liquid chromatography column brand names (provided in the Knowledge Database) and the reagents used to describe the stationary phases for these columns, an overall review of all the monographs concerned has been launched. The names...

More news

The European Pharmacopoeia (Ph. Eur.) has launched a public consultation on its new general chapter 2.8.26 on contaminant pyrrolizidine alkaloids. Users and concerned parties can submit their comments in Pharmeuropa 32.1 until 31...
The EDQM is pleased to announce that the European Paediatric Formulary is now available free of charge on a dedicated online platform. This is a major achievement for the PaedForm Working Party and all the stakeholders involved, since...
The Ph. Eur. Commission proposes to revise the general monograph on Substances for pharmaceutical use (2034). This proposal has been made further to the European Commission referral C(2019)2698 of 2 April 2019 and the review initiated...


04 February 2020 to 05 February 2020
Strasbourg, France
01 April 2020 to 02 April 2020
Strasbourg, France
Nitrosamine contamination in brief
In brief

In 2018, certain types of nitrosamines (N‑nitrosodiethylamine (NDEA) and N-nitrosodiethylamine (NDMA)) were detected in a number of active substances used in the treatment of hypertension and in related medicines. Nitrosamines are known as possible carcinogens for humans: only very low amounts are acceptable according to current regulatory requirements (ICH M7 “cohort of concern”). Their detection requires highly sensitive analytical methods. As clarified by the European Medicines Agency (EMA), their presence in active substances may be linked to several factors, e.g. from processing conditions to accidental introduction due to cross-contamination (from processes running in parallel on the same production lines) or recovery procedures for solvents, or also from degradation of the substances.

The Vision of the EDQM
In brief
  • A Directorate of the Council of Europe created in 1964.
  • A leading organisation that protects public health by enabling the development, supporting the implementation and monitoring the application of quality standards for safe medicines and their safe use.
  • Also develops guidance and standards in the areas of blood transfusion, organ transplantation and consumer health issues.
The European Pharmacopoeia
In brief
  • Main objective is to provide common quality standards to control the quality of medicines and of substances used in the manufacture of medicines (human and veterinary use).
  • Legally binding in European member states.
  • 39 signatory parties (including the EU) and 30 observers (including WHO and TFDA) as of March 2018.
Official Medicines Control Laboratories (OMCL)
In brief
  • A network of independent public laboratories appointed by the national authorities.
  • Around 70 laboratories provide human and technical resources to implement testing programmes.
  • 36 European countries and 5 countries outside Europe participate in the various activities and programmes.
The Certification of Suitability
In brief


  • Established in 1994.
  • Over 4,900 certificates covering more than 1,100 substances have been granted in more than 60 countries.
  • Assessment is jointly performed by a network of around 100 assessors from the national competent authorities and EDQM assessors.
  • Organises an inspection programme involving a network of around 30 inspectors from 20 different national competent authorities and the EDQM.


Meet the World Pharmacopoeias Symposium 20 February 2020

This one-day symposium will include background information on the International Meeting of World Pharmacopoeias and will explain the scope and content of the Good Pharmacopoeial Practices.

The speakers’ panel will bring together representatives of pharmacopoeias and stakeholders from around the world to present and discuss opportunities and challenges surrounding international co-operation and the harmonisation of pharmacopoeial texts.

This symposium is of interest to professionals from the pharmaceutical industry and regulatory agencies.

If you cannot make it to Strasbourg, you can register to attend this symposium remotely, by connecting to the internet link provided (webinar system).

More information available on the event webpage Meet the World Pharmacopoeias Symposium.

Latest products and services

How to order

Via our web store at in order to benefit from free handling charges (on publications only). Alternatively, you can send your order to the EDQM Sales section by:

  • post: EDQM – Council of Europe, 7 allée Kastner, CS 30026, 67081 Strasbourg, France
  • e-mail:

Invoices can be paid by credit card via internet or by bank transfer.

@Edqm_news on Twitter